Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 17, 10:00 PMSELLAS says galinpepimut-S cut risk of death 41% in its Phase 3 AML trial
Index
RUT
Market Cap
4.08B
Enterprise Value
3.95B
Income
-35.76M
Sales
0.00M
Book/sh
0.65
Cash/sh
0.66
Employees
13
IPO
Mar 12, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
30.92
P/C
30.28
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.92
Current Ratio
14.92
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.24
EPS next Q
-0.05
EPS this Y
20.00%
EPS next Y
-22.50%
EPS next 5Y
23.94%
EPS past 3/5Y
51.28% 34.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
30.50%
Sales Y/Y TTM
-
EPS Q/Q
20.45%
Sales Q/Q
-
Insider Own
1.11%
Insider Trans
0.00%
Inst Own
35.41%
Inst Trans
5.10%
ROA
-37.13%
ROE
-40.31%
ROIC
-27.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
93.14%
SMA50
79.96%
SMA200
123.61%
Trades
Shs Outstand
203.53M
Shs Float
201.59M
52W High
24.89 -19.54%
52W Low
1.39 1340.79%
Volatility
19.15% 13.37%
ATR (14)
2.30
RSI (14)
77.76
Beta
2.35
Rel Volume
4.93
Avg Volume
8.72M
Volume
24,120,780
Perf Week
137.85%
Perf Month
67.17%
Perf Quarter
49.46%
Perf Half Y
123.27%
Perf YTD
431.22%
Perf Year
1159.56%
Perf 3Y
1929.08%
Perf 5Y
191.51%
Perf 10Y
-99.63%
Prev Close
19.15
Price
20.03
Change %
4.58%
Consensus
Strong Buy
Avg. Price Target
$37.50
Implied Upside
+87.2%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 21, 2021Initiated
CCantor Fitzgerald
Overweight$18-10.1%
Nov 01, 2018Initiated
OPY logoOOppenheimer
Outperform
Apr 02, 2018Initiated
HH.C. Wainwright
Buy$11-45.1%
Mar 19, 2018Upgrade
MMaxim Group
Hold → Buy$13-35.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kalin Katherine BachDirectorNov 19 '25Buy1.5963,400100,806104,400Nov 21 08:45 AM
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
ScD h.c.Dr. Angelos M. Stergiou M.D.
Senior VP & CFOMr. John Thomas Burns CPA
MBADr. Dragan Cicic M.D.
VPMs. Stacy E. Yeung
Senior VP of Regulatory AffairsMr. Andrew Elnatan